Litigation Details for Ahold USA, Inc. v. Allergan, Inc. (E.D.N.Y 2018)
✉ Email this page to a colleague
Ahold USA, Inc. v. Allergan, Inc. (E.D.N.Y 2018)
| Docket | ⤷ Subscribe | Date Filed | 2018-02-14 |
| Court | District Court, E.D. New York | Date Terminated | 2018-06-06 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Nina Gershon |
| Jury Demand | Plaintiff | Referred To | Lois Bloom |
| Patents | 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930; 9,248,191 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Ahold USA, Inc. v. Allergan, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Subscribe .
Details for Ahold USA, Inc. v. Allergan, Inc. (E.D.N.Y 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-01-16 | 1 | second wave patents, U.S. Patent Nos. 8,629,111 (“the ’111 patent”), 8,633,162 (“the ’162 patent”), 8,642,556…the six second wave patents which it claims cover Restasis: U.S. Patent No. 8,629,111 (issued January 14…Orange Book listing 8,629,111 (the ’111 patent) January 14, 2014 … original patent filings. However, for these secondary patent filings, the original patents become “prior…1995, the PTO issued U.S. Patent No. 5,474,979 (“the Ding I patent”). This patent disclosed Allergan’s cyclosporine | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
